Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Authors:
- 1 February 2022
- journal article
- review article
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (1) , 10-15.e2
Abstract
No abstract availableKeywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Case of ketoacidosis by a sodium‐glucose cotransporter 2 inhibitor in a diabetic patient with a low‐carbohydrate dietJournal of Diabetes Investigation, 2015
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and HypertensionDiabetes Care, 2014
- The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird methodBMC Medical Research Methodology, 2014
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJournal of Clinical Investigation, 2014
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012JAMA, 2014
- SGLT inhibitors in management of diabetesThe Lancet Diabetes & Endocrinology, 2013
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid studyBMC Medical Research Methodology, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Preparation and Characterisation of Niobium (V) β-DiketonatesSynthesis and Reactivity in Inorganic, Metal-Organic, and Nano-Metal Chemistry, 1983